MCID: SBC017
MIFTS: 45

Sebaceous Gland Disease

Categories: Endocrine diseases, Skin diseases

Aliases & Classifications for Sebaceous Gland Disease

MalaCards integrated aliases for Sebaceous Gland Disease:

Name: Sebaceous Gland Disease 12 15 17
Sebaceous Gland Diseases 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9098
ICD9CM 36 706.1
ICD10 34 L70.8

Summaries for Sebaceous Gland Disease

Disease Ontology : 12 A skin disease that is located in the sebaceous gland.

MalaCards based summary : Sebaceous Gland Disease, also known as sebaceous gland diseases, is related to neurofibromatosis, type ii and mycobacterium chelonae, and has symptoms including pruritus and exanthema. An important gene associated with Sebaceous Gland Disease is PLIN2 (Perilipin 2), and among its related pathways/superpathways are Pathways in cancer and IL-1 Family Signaling Pathways. The drugs Clindamycin and Benzoyl peroxide have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and brain, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Sebaceous glands are microscopic exocrine glands in the skin that secrete an oily or waxy matter, called... more...

Related Diseases for Sebaceous Gland Disease

Diseases related to Sebaceous Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 neurofibromatosis, type ii 31.5 DEFB4A IL1A SHBG TLR2
2 mycobacterium chelonae 10.3 CXCL8 TLR2
3 mycobacterium marinum 10.3 CXCL8 TLR2
4 mycobacterium kansasii 10.3 CXCL8 TLR2
5 47, xxy 10.3 AR SHBG
6 neurosyphilis 10.3 CXCL8 TLR2
7 postmenopausal atrophic vaginitis 10.3 AR SHBG
8 androgen insensitivity, partial 10.3 AR SHBG
9 meibomian cyst 10.3 AR PLIN2
10 haemophilus influenzae 10.3 CXCL8 TLR2
11 alopecia, androgenetic, 1 10.2 AR SHBG
12 marasmus 10.2 IGF1 SHBG
13 mycobacterium abscessus 10.2 CXCL8 TLR2
14 corneal abscess 10.2 AR DEFB4A
15 cervicitis 10.2 CXCL8 DEFB4A
16 cone-rod dystrophy 12 10.2 IGF1 PLIN2
17 septic arthritis 10.1 CXCL8 DEFB4A TLR2
18 anal canal squamous cell carcinoma 10.1 NCSTN PSENEN
19 androgenic alopecia 10.1 AR SHBG
20 vaginal disease 10.1 CXCL8 DEFB4A
21 leukoregulin 10.1 CXCL8 IL1A
22 complete androgen insensitivity syndrome 10.1 AR SHBG
23 bacterial infectious disease 10.1 CXCL8 DEFB4A TLR2
24 scabies 10.1 CXCL8 IL1A
25 male reproductive system disease 10.1 AR IGF1 SHBG
26 prostatic hyperplasia, benign 10.1 AR SHBG
27 vaginitis 10.1 AR CXCL8 DEFB4A
28 male reproductive organ cancer 10.1 AR IGF1 SHBG
29 gonadal disease 10.0 AR IGF1 SHBG
30 appendix carcinoid tumor 10.0 MLH1 MSH2
31 colorectal cancer, hereditary nonpolyposis, type 7 10.0 MLH1 MSH2
32 vulvovaginal candidiasis 10.0 DEFB4A TLR2
33 adenosquamous colon carcinoma 10.0 MLH1 MSH2
34 sebaceous adenoma 10.0 MLH1 MSH2
35 lower lip cancer 10.0 MLH1 MSH2
36 breast disease 10.0 IGF1 MSH2 SHBG
37 idiopathic inflammatory myopathy 10.0 AARS IL1A
38 chlamydia 10.0 CXCL8 IL1A TLR2
39 proteasome-associated autoinflammatory syndrome 1 10.0 CXCL8 IL1A TLR2
40 periodontitis 10.0 CXCL8 IL1A TLR2
41 oral candidiasis 9.9 CXCL8 DEFB4A IL1A
42 tonsillitis 9.9 CXCL8 DEFB4A IL1A
43 melanocytic nevus syndrome, congenital 9.9 MLH1 MSH2
44 muir-torre syndrome 9.9 MLH1 MSH2 PLIN2
45 anal fistula 9.8 DEFB4A MLH1 MSH2
46 gastrointestinal system disease 9.8 CXCL8 MLH1 MSH2
47 bacterial vaginosis 9.8 CXCL8 DEFB4A IL1A TLR2
48 gingivitis 9.8 CXCL8 DEFB4A IL1A TLR2
49 periodontal disease 9.8 CXCL8 DEFB4A IL1A TLR2
50 colorectal adenoma 9.8 IGF1 MLH1 MSH2

Graphical network of the top 20 diseases related to Sebaceous Gland Disease:



Diseases related to Sebaceous Gland Disease

Symptoms & Phenotypes for Sebaceous Gland Disease

UMLS symptoms related to Sebaceous Gland Disease:


pruritus, exanthema

MGI Mouse Phenotypes related to Sebaceous Gland Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 AR IGF1 IL1A MLH1 MSH2 NCSTN
2 immune system MP:0005387 9.81 AR IGF1 IL1A MLH1 MSH2 NCSTN
3 integument MP:0010771 9.61 AARS AR IGF1 IL1A MLH1 MSH2
4 neoplasm MP:0002006 9.17 AR IGF1 IL1A MLH1 MSH2 NCSTN

Drugs & Therapeutics for Sebaceous Gland Disease

Drugs for Sebaceous Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
2
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
3
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
4
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-72-7 338
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
6
Isotretinoin Approved Phase 4,Phase 1,Not Applicable 4759-48-2 5538 5282379
7
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
9
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
10
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 123-99-9 2266
11
Caffeine Approved Phase 4,Phase 1 58-08-2 2519
12
Adapalene Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106685-40-9 60164
13
Zinc Approved, Investigational Phase 4 7440-66-6 32051
14
leucovorin Approved Phase 4,Phase 3,Phase 1 58-05-9 6006 143
15
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 1 80-08-0 2955
16
Tetracycline Approved, Vet_approved Phase 4,Phase 2 60-54-8 5353990
17
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
18
tannic acid Approved Phase 4 1401-55-4
19
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757
20
Ethinyl Estradiol Approved Phase 4,Phase 3 57-63-6 5991
21
Norgestrel Approved Phase 4 6533-00-2 13109
22
Desogestrel Approved Phase 4 54024-22-5 40973
23
Polyestradiol phosphate Approved Phase 4,Phase 3 28014-46-2
24
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
25
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
26
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
27
Cyproterone Acetate Approved, Investigational Phase 4,Phase 3 427-51-0
28
Coal tar Approved Phase 4,Not Applicable 8007-45-2
29
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10118-90-8 5281021
30
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492 6473866
31
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65277-42-1 47576
32
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
33
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
34
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
35
Chamomile Approved, Experimental, Investigational Phase 4
36
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
37
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 302-79-4 5538 444795
38
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
40
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3 7440-70-2 271
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 1406-16-2
42
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3 50-14-6 5280793
43
Nadifloxacin Investigational Phase 4,Phase 3 124858-35-1
44
Rosemary Experimental Phase 4
45 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
46 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 Keratolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Clindamycin palmitate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Clindamycin phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 402)
# Name Status NCT ID Phase Drugs
1 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
2 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
3 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
4 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
5 Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia Completed NCT03626298 Phase 4 Adapalene;Nicotinamide, ABA and Zinc PCA;Placebos
6 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Completed NCT02959970 Phase 4 dapsone gel
7 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Completed NCT02944461 Phase 4 Dapsone 7.5 % gel
8 A Treatment for Severe Inflammatory Acne Subjects Completed NCT02899000 Phase 4 Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel;Oral doxycycline hyclate
9 Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products Completed NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
10 Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris Completed NCT02721173 Phase 4 Tazarotene 0.1% gel plus clindamycin 1% gel;Adapalene 0.1% gel plus clindamycin 1% gel
11 Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris Completed NCT02589405 Phase 4 Benzoyl Peroxide
12 DUAC® Early Onset Efficacy Study in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
13 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Completed NCT02524665 Phase 4
14 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
15 Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
16 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Completed NCT02032407 Phase 4 Dapsone Gel
17 Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Completed NCT01951417 Phase 4 Adapalene/BPO Gel
18 Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
19 U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne Completed NCT01706263 Phase 4 MAXCLARITY II (2.5% BPO) Foam Cleanser;MAXCLARITY II (2.5% BPO) Foam Treatment;MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
20 U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Completed NCT01706250 Phase 4
21 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
22 Effect of Samples on Acne Treatment With Epiduo® Gel Completed NCT01504204 Phase 4 Adapalene + benzoyl peroxide samples;Adapalene + benzoyl peroxide from standard tube
23 An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment Completed NCT01466673 Phase 4 Ethinyl estradiol/Norgestimate (EE/NGM);Ethinyl estradiol/Desogestrel (EE/DSG)
24 A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory Completed NCT01404130 Phase 4 Isotretinoin
25 Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin Completed NCT01387048 Phase 4 skinoren;differin;skinoren
26 A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products Completed NCT01313728 Phase 4 Dapsone plus Tretinoin Gel;Tretinoin Gel
27 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne Completed NCT01231334 Phase 4 Dapsone plus Adapalene;Clindamycin/benzoyl peroxide plus Adapalene
28 Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris Completed NCT01209949 Phase 4 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
29 Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel Completed NCT01188538 Phase 4 Epiduo gel;BPO
30 Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Completed NCT01149330 Phase 4 Adapalene-BPO Gel
31 Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris Completed NCT01047189 Phase 4 clindamycin phosphate 1.2% and tretinoin 0.025%;clindamycin 1% gel;tretinoin 0.025% cream
32 A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris Completed NCT01016977 Phase 4 Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene;clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
33 Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications Completed NCT01015638 Phase 4 Clindamycin and BPO 5% gel;Clindamycin phosphate and benzoyl peroxide 2.5% gel.
34 Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications Completed NCT00964366 Phase 4 clindamycin and benzoyl peroxide;Dapsone gel
35 A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne Completed NCT00964223 Phase 4 Clindamycin and benzoyl peroxide gel (Duac® Topical Gel);benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
36 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00952523 Phase 4 Tretinoin Facial Gel;Adapalene/Benzoyl Peroxide Facial Gel
37 Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications Completed NCT00926367 Phase 4 Clindamycin and benzoyl peroxide;benzoyl peroxide 2.5% and adapalene 0.1% gel
38 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
39 A Study of Different Use Regimens Using Two Acne Treatments Completed NCT00907257 Phase 4 benzoyl peroxide wash;Tretinoin gel
40 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne Completed NCT00887484 Phase 4 BENZOYL PEROXIDE/ CLINDAMYCIN;BENZOYL PEROXIDE/ ADAPALENE
41 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne Completed NCT00841776 Phase 4 Duac;Ziana gel
42 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris Completed NCT00835198 Phase 4 Dapsone; Tretinoin;Tretinoin
43 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
44 Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne Completed NCT00807014 Phase 4 Duac Gel;Differin gel
45 Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring Completed NCT00795327 Phase 4
46 Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris Completed NCT00757523 Phase 4 Epiduo Gel;Duac Gel
47 Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
48 Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face. Completed NCT00714714 Phase 4 Adapalene Gel;Tretinoin Gel
49 Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris Completed NCT00696449 Phase 4 Adapalene
50 Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris Completed NCT00671749 Phase 4 adapalene gel, 0.3%;clindamycin/benzoyl peroxide gel

Search NIH Clinical Center for Sebaceous Gland Disease

Genetic Tests for Sebaceous Gland Disease

Anatomical Context for Sebaceous Gland Disease

MalaCards organs/tissues related to Sebaceous Gland Disease:

42
Skin, Testes, Brain, Bone, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Sebaceous Gland Disease:

20
The Sebaceous Gl

Publications for Sebaceous Gland Disease

Articles related to Sebaceous Gland Disease:

# Title Authors Year
1
Primary sebocytes and sebaceous gland cell lines for studying sebaceous lipogenesis and sebaceous gland diseases. ( 29451719 )
2018
2
New pharmaceutical concepts for sebaceous gland diseases: implementing today's pre-clinical data into tomorrow's daily clinical practice. ( 22250709 )
2012
3
Risk factors for sebaceous gland diseases and their relationship to gastrointestinal dysfunction in Han adolescents. ( 18837699 )
2008

Variations for Sebaceous Gland Disease

Expression for Sebaceous Gland Disease

Search GEO for disease gene expression data for Sebaceous Gland Disease.

Pathways for Sebaceous Gland Disease

GO Terms for Sebaceous Gland Disease

Cellular components related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.96 MLH1 MSH2
2 gamma-secretase complex GO:0070765 8.62 NCSTN PSENEN

Biological processes related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.88 AR CXCL8 IL1A TLR2
2 positive regulation of gene expression GO:0010628 9.86 AR IGF1 IL1A TLR2
3 inflammatory response GO:0006954 9.85 CXCL8 IL1A PSTPIP1 TLR2
4 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 IL1A
5 membrane protein ectodomain proteolysis GO:0006509 9.57 NCSTN PSENEN
6 somatic hypermutation of immunoglobulin genes GO:0016446 9.54 MLH1 MSH2
7 isotype switching GO:0045190 9.52 MLH1 MSH2
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.51 AR IGF1
9 cell activation GO:0001775 9.49 IGF1 TLR2
10 response to molecule of bacterial origin GO:0002237 9.48 CXCL8 TLR2
11 amyloid precursor protein metabolic process GO:0042982 9.46 NCSTN PSENEN
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 MLH1 MSH2
13 Notch receptor processing GO:0007220 9.4 NCSTN PSENEN
14 amyloid precursor protein catabolic process GO:0042987 9.37 NCSTN PSENEN
15 Notch receptor processing, ligand-dependent GO:0035333 9.32 NCSTN PSENEN
16 amyloid-beta formation GO:0034205 9.26 NCSTN PSENEN
17 positive regulation of isotype switching to IgA isotypes GO:0048298 9.16 MLH1 MSH2
18 somatic recombination of immunoglobulin gene segments GO:0016447 8.96 MLH1 MSH2
19 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MLH1 MSH2

Molecular functions related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 9.26 AR SHBG
2 mismatched DNA binding GO:0030983 9.16 MLH1 MSH2
3 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH2
4 androgen binding GO:0005497 8.62 AR SHBG

Sources for Sebaceous Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....